ALLMedicine™ Gastrointestinal Hemorrhage Center

May 14th, 2022 - Acute gastrointestinal (GI) bleeding is one of the leading causes of emergency department visits and hospital admissions. CT angiography (CTA) has had an expanding role in the evaluation of acute GI bleeding because it is rapidly performed, widely...

May 10th, 2022 - Primary duodenal cancer (PDC) is rare, especially signet-ring cell carcinoma (SRCC) of the duodenal bulb, and it is commonly misdiagnosed as an ulceration. Here, we report a rare case of SRCC of the duodenal bulb presenting with gastrointestinal h...

May 1st, 2022 - Gastrointestinal Hemorrhage After Antidepressant Drug Use: A Case Report.|2022|Huang H,Zhang P,Wu L,Lai J,Hu S,|adverse effects,chemically induced,complications,

Apr 22nd, 2022 - Upper gastrointestinal hemorrhage (UGIH) is one of the most common gastrointestinal emergencies, and is associated with significant morbidity and mortality. Acute upper gastrointestinal hemorrhage (AUGIH) management guidelines call for aggressive ...

Apr 20th, 2022 - Acute-on-chronic liver failure (ACLF) is a syndrome characterized by acute decompensation of chronic liver disease associated with organ failures and very high short-term mortality. To assess the incidence and factors predisposing to ACLF in patie...

Sep 30th, 2015 - This Guideline is an official statement of the European Society of Gastrointestinal Endoscopy (ESGE). It addresses the diagnosis and management of nonvariceal upper gastrointestinal hemorrhage (NVUGIH). Main Recommendations MR1. ESGE recommends im...

Apr 22nd, 2022 - Upper gastrointestinal hemorrhage (UGIH) is one of the most common gastrointestinal emergencies, and is associated with significant morbidity and mortality. Acute upper gastrointestinal hemorrhage (AUGIH) management guidelines call for aggressive ...

May 4th, 2021 - The study described in this report will be approved by the ethics committee of Yonsei University School of Medicine, Seoul, Korea. Between July 2012 and February 2013, 380 patients fulfilled the inclusion criteria, 380 of whom were included in the...

Jul 21st, 2020 - Specific aims of this study : To examine the influences of acute gastrointestinal hemorrhage on the serological or urinary level of novel renal biomarkers in patients with cirrhosis. To investigate the ability of novel biomarkers to predict the de...

Apr 20th, 2020 - The purpose of this study is to evaluate the efficacy and safety of fecal microbiome transplantation in patients with steroid resistant/dependent acute gastrointestinal graft-versus-host disease (GVHD). Inclusion criteria: Age>= 14 yrs ≤60 yrs. Di...

Feb 11th, 2020 - Study procedures Written informed consent before study specific procedures are undertaken. The investigators will explain the contents of the trial especially the information about the possible side effects, other alternative treatment and the rig...

Oct 6th, 2021 - The ovarian cancer armamentarium continues to evolve with novel agents, such as antibody-drug conjugates (ADCs) and immunotherapy, even with clinical trial findings showing mixed, yet intriguing, results with these classes of agents. In a prese...

Aug 18th, 2021 - For patients with mantle cell lymphoma (MCL) who have progressed after treatment with a BTK inhibitor such as ibrutinib (Imbruvica), there is an unmet need for the development of safe and effective targeted therapies to improve otherwise dismal ou...

Apr 21st, 2021 - The novel T-cell–engaging bispecific antibody glofitamab (RO7082859) demonstrated encouraging clinical activity, with frequent and durable complete remissions, and a manageable toxicity profile in patients with predominantly refractory, aggressive...

Dec 20th, 2020 - Nicholas J. Vogelzang, MD Cabozantinib (XL184), a novel tyrosine kinase inhibitor, caused the deaths of 6 patients in a phase II clinical trial, according to data presented at ASCO’s annual meeting. The fatalities had not been reported with the c...

Dec 20th, 2020 - Grant A. McArthur, MBBS, PhD Treatment with atezolizumab (Tecentriq) in combination with vemurafenib (Zelboraf) and cobimetinib (Cotellic) was found to significantly improve progression-free survival (PFS) and produce durable responses versus vem...